NCT05962606 2026-03-18
Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia.
Aptarion Biotech AG
Phase 2 Completed
Aptarion Biotech AG
National Cancer Institute (NCI)
BioAegis Therapeutics Inc.
Nantes University Hospital
M.D. Anderson Cancer Center
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
MedImmune LLC